Arcutis Biotherapeutics (ARQT) officer sells 222 shares to cover RSU tax

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. officer Patrick Burnett reported an open-market sale of 222 shares of common stock at $21.05 per share. According to the footnote, this sale was made solely to cover tax withholding obligations tied to the vesting of Restricted Stock Units. After the transaction, Burnett directly owned 120,244 shares, so the sale represents a very small portion of his holdings and reflects a compensation-related tax event rather than a discretionary reduction in his investment.

Insider Trade Summary 10b5-1

Net Seller: 222 shares ($4,673)

Net Sell 1 txn

Insider Burnett Patrick

Role See Remarks

Sold 222 shs ($5K)

Type	Security	Shares	Price	Value
Sale	Common Stock	222	$21.05	$5K

Holdings After Transaction: Common Stock — 120,244 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 222 shares Sale price: $21.05 per share Shares held after transaction: 120,244 shares

3 metrics

Shares sold 222 shares Open-market sale on transaction date

Sale price $21.05 per share Reported transaction price

Shares held after transaction 120,244 shares Direct ownership after sale

Key Terms

Restricted Stock Units, tax withholding obligations, open-market sale

3 terms

Restricted Stock Units financial

"in connection with the vesting of Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"shares sold by the Reporting Person to cover tax withholding obligations"

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Burnett Patrick

(Last) (First) (Middle)

C/O ARCUTIS BIOTHERAPEUTICS, INC.

3027 TOWNSGATE ROAD, SUITE 300

(Street)

WESTLAKE VILLAGE CALIFORNIA 91361

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		S(1)		222	D	$21.05	120,244	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units.

Remarks:

Reporting Person's Title: EVP, Chief Medical Officer

	/s/ Latha Vairavan, as Attorney-in-Fact for Patrick Burnett	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Arcutis Biotherapeutics (ARQT) report for Patrick Burnett?

Arcutis Biotherapeutics reported that officer Patrick Burnett sold 222 shares of common stock. The shares were sold at $21.05 each to cover tax withholding obligations arising from the vesting of Restricted Stock Units, according to the filing footnote.

Why did Patrick Burnett sell Arcutis Biotherapeutics (ARQT) shares in this Form 4?

The filing states that Patrick Burnett sold the shares to cover tax withholding obligations. These obligations arose in connection with the vesting of Restricted Stock Units, indicating the sale was related to compensation and tax management rather than a discretionary share disposal.

How many Arcutis Biotherapeutics (ARQT) shares did Patrick Burnett sell and at what price?

Patrick Burnett sold 222 shares of Arcutis Biotherapeutics common stock. The reported sale price was $21.05 per share in an open-market transaction, as disclosed in the Form 4 insider trading report filed with regulators.

How many Arcutis Biotherapeutics (ARQT) shares does Patrick Burnett hold after this transaction?

After the reported sale, Patrick Burnett directly holds 120,244 shares of Arcutis Biotherapeutics common stock. This indicates the transaction involved only a small fraction of his overall position, consistent with a tax-related sale tied to equity compensation vesting.

Does the Patrick Burnett Form 4 for Arcutis Biotherapeutics (ARQT) indicate a discretionary sale?

The Form 4 describes the transaction as an open-market sale, but the footnote clarifies it was to cover tax withholding obligations on Restricted Stock Unit vesting. This suggests the sale is compensation-related and mechanistic, not a discretionary move to reduce his share ownership.